Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284179 | 0.94 | RARB (0.62) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL1262098 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL5383508 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL31124203 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL8913329 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL6473001 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL1561875 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL6473267 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL3442617 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA | |
| SCHEMBL31124115 | 0.92 | RARB (0.64) | RARBCYP4A11ALDH1A1MEN1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906933-B2 | Coupled peptide chain for dissolving poorly soluble polypeptides and application thereof for separation and purification in liquid chromatography | SPEC-CHEM INDUSTRY INC. (CN) | 2021-02-02 | — | — | US | claimed |
| CN-111655251-A | Esters of hydroxybenzoic acids for the treatment of rhinoviruses | 酶公司 | 2020-09-11 | — | — | CN | claimed |
| US-20180186830-A1 | COUPLED PEPTIDE CHAIN FOR DISSOLVING POORLY SOLUBLE POLYPEPTIDES AND APPLICATION THEREOF FOR SEPARATION AND PURIFICATION IN LIQUID CHROMATOGRAPHY | SPEC-CHEM INDUSTRY INC. (CN) | 2018-07-05 | — | — | US | claimed |
| CN-105001298-B | A kind of synthesis isolation and purification method of indissoluble polypeptide | 南京斯拜科生化实业有限公司 | 2018-01-02 | — | — | CN | claimed |
| CN-105001307-A | Coupling peptide chain capable of dissolving indissolvable polypeptide and application of the same in separation and purification in liquid chromatogram | SPEC CHEM INDUSTRY INC | 2015-10-28 | — | — | CN | claimed |
| CN-105001298-A | Synthesis-separation and purification method for indissolvable polypeptide | SPEC CHEM INDUSTRY INC | 2015-10-28 | — | — | CN | claimed |
| EP-2667897-A1 | PARABEN COMPOSITIONS | Anterios, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| US-20120321571-A1 | PARABEN COMPOSITIONS | ANTERIOS, INC. (US) | 2012-12-20 | — | — | US | claimed |
| WO-2012103040-A1 | PARABEN COMPOSITIONS | ANTERIOS, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| EP-1368016-B1 | PARENTERAL DOSAGE FORMS COMPRISING A SUSPENSION OF TRAMADOL SALT AND DICLOFENAC SALT | GRUENENTHAL GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-1368016-A1 | PARENTERAL DOSAGE FORMS COMPRISING A SUSPENSION OF TRAMADOL SALT AND DICLOFENAC SALT | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002043723-A1 | PARENTERAL DOSAGE FORMS COMPRISING A SUSPENSION OF TRAMADOL SALT AND DICLOFENAC SALT | Grünenthal GmbH (DE) | 2002-06-06 | — | — | WO | claimed |
| JP-7075666-A | — | — | None | — | — | JP | disclosed |
| EP-4692041-A1 | METHOD FOR PRODUCING BIO-DERIVED ESTER COMPOUND, BIO-DERIVED ESTER COMPOUND PRODUCED THEREBY, COSMETIC OR DETERGENT CONTAINING BIO-DERIVED ESTER COMPOUND, AND METHOD FOR REDUCING ODOR OF ESTER COMPOUND | ADEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-4711900-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| US-4649044-A | DISCOLORATION INHIBITION | LION CORPORATION (JP) | 1987-03-10 | — | — | US | disclosed |
| US-4466954-A | CONTAINING DESTRANASE | LION CORPORATION (JP) | 1984-08-21 | — | — | US | disclosed |
| US-4024131-A | ANTIINFLAMMATORY | PLURICHEMIE ANSTALT (FL) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | RARB 1947/4885CYP4A11 654/4885ALDH1A1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.